• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    54 Biggest Movers From Yesterday

    4/20/22 5:43:34 AM ET
    $ACC
    $AIM
    $ANNX
    $ARQQ
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACC alert in real time by email

    Gainers

    • Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a deal to acquire the company for $10.50 per share in cash.
    • Sono Group N.V. (NASDAQ:SEV) climbed 65.2% to close at $7.60.
    • Sharps Technology, Inc. (NASDAQ:STSS) shares gained 40.5% to close at $2.43 after dipping 18% on Monday. The company recently priced its IPO at $4.25 per share.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) gained 37% to close at $0.2010 as the company posted a narrower FY21 loss.
    • Baosheng Media Group Holdings Limited (NASDAQ:BAOS) rose 33.3% to close at $0.78.
    • Terran Orbital Corporation (NYSE:LLAP) gained 28.4% to settle at $4.98.
    • MedAvail Holdings, Inc. (NASDAQ:MDVL) jumped 26.4% to close at $2.73.
    • Axsome Therapeutics, Inc. (NASDAQ:AXSM) climbed 25.1% to close at $40.92 after the company announced it received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the NDA for its AXS-05.
    • Charge Enterprises, Inc. (NASDAQ:CRGE) jumped 24.1% to close at $7.93.
    • Zymergen Inc. (NASDAQ:ZY) gained 22.6% to close at $2.01.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) gained 22% to close at $44.65 after the company raised its Q3 guidance above analyst estimates.
    • Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) rose 21.9% to close at $1.45. Clarus Therapeutics reported presentation of new data for its JATENZO at Androgen Society Annual Meeting Apr. 23 at 10:15 a.m. EDT.
    • Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) gained 20.9% to settle at $1.33 after the company announced results from its OTC draft label comprehension study for STENDRA.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) rose 18.5% to close at $4.10.
    • AIM ImmunoTech Inc. (NYSE:AIM) surged 15.5% to close at $1.12. AIM ImmunoTech recently announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer.
    • Leap Therapeutics, Inc. (NASDAQ:LPTX) gained 15.4% to settle at $1.65.
    • Tricida, Inc. (NASDAQ:TCDA) rose 15.4% to close at $11.75.
    • Candel Therapeutics, Inc. (NASDAQ:CADL) climbed 15% to close at $5.51.
    • ThredUp Inc. (NASDAQ:TDUP) jumped 14.4% to close at $8.81.
    • Silvergate Capital Corporation (NYSE:SI) climbed 13.2% to settle at $131.67 after the company reported better-than-expected Q1 EPS results.
    • Evoke Pharma, Inc. (NASDAQ:EVOK) gained 13.2% to close at $0.4245. Evoke Pharma reported approval of its GIMOTI to Texas Medicaid Preferred Drug List.
    • American Campus Communities, Inc. (NYSE:ACC) climbed 12.5% to close at $64.80 after the company announced Blackstone Core+ Perpetual Capital Vehicles will acquire the company for $65.47 per share in cash.
    • Gogoro Inc. (NASDAQ:GGR) rose 11.8% to close at $8.94. Gogoro’s Chief Executive Officer Horace Luke said that the company has an adequate amount of chips to meet its needs, Reuters reported.
    • Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) gained 11.7% to close at $0.99 after the company announced the regulatory approval of Lymphoaim by the Central Drugs Standard Control Organisation in India.
    • Annexon, Inc. (NASDAQ:ANNX) gained 11.4% to close at $2.35. Annexon CEO Douglas Love reported the purchase of 60,000 shares at an average price of $2.45 per share.
    • Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) gained 9.2% to close at $3.20.
    • Party City Holdco Inc. (NYSE:PRTY) rose 8.1% to close at $3.86.
    • WeWork Inc. (NYSE:WE) gained 8.1% to close at $6.41 after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $10 price target.
    • Pulse Biosciences, Inc. (NASDAQ:PLSE) gained 7.3% to close at $3.38.
    • Sentage Holdings Inc. (NASDAQ:SNTG) rose 6.7% to close at $0.80.
    • Sidus Space, Inc. (NASDAQ:SIDU) rose 6.5% to close at $2.97 following a 7% decline on Monday. Sidus Space recently appointed Teresa Burchfield as its Chief Financial Officer.
    • Zendesk, Inc. (NYSE:ZEN) rose 6.1% to close at $129.12 after Bloomberg late Monday reported the company is working with Qatalyst on a potential sale.


    Losers

    • System1, Inc. (NYSE:SST) shares fell 34.2% to close at $13.45 on Tuesday as the company disclosed a previously-issued (from Feb. 9, 2022) shelf registration statement went into effect.
    • BRC Inc. (NYSE:BRCC) fell 23.1% to close at $17.68.
    • Lyra Therapeutics, Inc. (NASDAQ:LYRA) dipped 20.9% to settle at $5.48.
    • Lyra Therapeutics recently reported a private placement for gross proceeds of $100.5 million.
    • Mawson Infrastructure Group, Inc. (NASDAQ:MIGI) fell 18.7% to close at $4.04. Mawson Infrastructure Group said March self-mined bitcoin production up 336% year over year to 170 bitcoin.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) fell 16.4% to close at $10.45.
    • BitNile Holdings, Inc. (NYSE:NILE) dropped 14.1% to settle at $0.6076. BitNile recently reported FY21 sales results up from last year.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) fell 14% to close at $1.41.
    • Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) declined 13.5% to close at $3.90.
    • DENTSPLY SIRONA Inc. (NASDAQ:XRAY) fell 13.4% to close at $42.20 after the company issued Q1 2022 adjusted EPS guidance below estimates and announced the appointment of John Groetelaars as Interim Chief Executive Officer.
    • Aytu BioPharma, Inc. (NASDAQ:AYTU) fell 12.6% to settle at $0.7975. Aytu BioPharma announced Fast Track designation was granted for AR101 for the treatment of vascular Ehlers-Danlos syndrome.
    • CEL-SCI Corporation (NYSE:CVM) dipped 12% to close at $3.23.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) shares fell 11.3% to close at $22.46.
    • Enservco Corporation (NYSE:ENSV) fell 10.5% to close at $3.25. Enservco shares gained 38% on Monday after the company announced the delay of its 2021 10-K filing to adjust for its utilization of certain deferred tax liabilities in 2021.
    • Houston American Energy Corp. (NYSE:HUSA) dropped 10% to settle at $4.50.
    • Jupai Holdings Limited (NYSE:JP) fell 10% to close at $0.54.
    • MoonLake Immunotherapeutics (NASDAQ:MLTX) fell 7.9% to close at $5.52.
    • Casa Systems, Inc. (NASDAQ:CASA) fell 7.9% to close at $6.54. Casa Systems shares jumped over 82% on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions. Verizon will also make an investment of approximately $40 million in Casa, resulting in a 9.9% ownership stake.
    • FLEX LNG Ltd. (NYSE:FLNG) shares fell 7.9% to close at $29.28.
    • Energy Vault Holdings, Inc. (NYSE:NRGV) fell 7.4% to settle at $13.00.
    • U.S. Energy Corp. (NASDAQ:USEG) fell 8.4% to close at $4.58.
    • Indonesia Energy Corporation Limited (NYSE:INDO) shares fell 6.6% to close at $24.09.
    • Barnwell Industries, Inc. (NYSE:BRN) dropped 5.4% to close at $2.65.
    Get the next $ACC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACC
    $AIM
    $ANNX
    $ARQQ

    CompanyDatePrice TargetRatingAnalyst
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Super Micro Computer Inc.
    $SMCI
    1/13/2026$26.00Sell
    Goldman
    Axsome Therapeutics Inc.
    $AXSM
    1/8/2026$204.00Overweight → Equal-Weight
    Morgan Stanley
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Regeneron Pharmaceuticals Inc.
    $REGN
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    DENTSPLY SIRONA Inc.
    $XRAY
    12/9/2025$12.00Underweight
    Barclays
    Regeneron Pharmaceuticals Inc.
    $REGN
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Endeavor Blockchain, Llc bought $192,502 worth of shares (42,100 units at $4.57), decreasing direct ownership by 100% to 4,397 units (SEC Form 4)

    4 - Mawson Infrastructure Group Inc. (0001218683) (Issuer)

    1/30/26 7:58:02 PM ET
    $MIGI
    Finance: Consumer Services
    Finance

    Large owner Endeavor Blockchain, Llc bought $290,400 worth of shares (60,000 units at $4.84), increasing direct ownership by 4% to 1,460,000 units (SEC Form 4)

    4 - Mawson Infrastructure Group Inc. (0001218683) (Issuer)

    1/26/26 7:22:56 PM ET
    $MIGI
    Finance: Consumer Services
    Finance

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Super Micro Computer with a new price target

    Goldman resumed coverage of Super Micro Computer with a rating of Sell and set a new price target of $26.00

    1/13/26 9:18:14 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    Axsome Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Axsome Therapeutics from Overweight to Equal-Weight and set a new price target of $204.00

    1/8/26 8:36:26 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM's strategic emphasis on pancreatic cancer. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:40 PM ESTPresenter: Thomas K. Equels, MS JD, Chief Executive Officer Registration Link: Here S

    2/6/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mawson Infrastructure Group Inc. Releases Preliminary Unaudited Results for Fourth Quarter and Fiscal Year 2025

    MIDLAND, Pa., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group, Inc. (NASDAQ:MIGI) ("Mawson" or the "Company") (NASDAQ:MIGI) today announced preliminary, unaudited financial results for the Fourth Quarter and Fiscal Year ended December 31, 2025. Preliminary Estimated Results for the Fourth Quarter and Year Ended December 31, 2025Our expectations with respect to our revenue, cost of revenues, gross profit, gross profit margin and net loss for the fourth quarter and year ended December 31, 2025 discussed below are based upon management estimates for the period. Our expectations are subject to the completion of our financial closing procedures and any adjustments that may resu

    2/6/26 6:00:00 AM ET
    $MIGI
    Finance: Consumer Services
    Finance

    Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

    Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA. Key study findings include: 100% procedural success of

    2/5/26 7:00:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    SEC Filings

    View All

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/6/26 5:06:37 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Super Micro Computer Inc.

    10-Q - Super Micro Computer, Inc. (0001375365) (Filer)

    2/6/26 5:03:49 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    SEC Form 8-K filed by Lyra Therapeutics Inc.

    8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

    2/6/26 4:12:23 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sainz Maria

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/6/26 9:21:10 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sainz Maria

    3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/6/26 9:18:07 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Leadership Updates

    Live Leadership Updates

    View All

    CISO Global Partners with TeleDental to Launch CyberSimple® Powered by CHECKLIGHT® to Protect Dental Clinics From Cyber Threats

    Scottsdale, AZ, Jan. 15, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO), a leading provider of AI-powered cybersecurity software and compliance services, today announced a strategic partnership with TeleDental.com and DentalChat.com to offer Cyber Assurance Group's CyberSimple® powered by CHECKLIGHT®, delivering cybersecurity and financial protection purpose-built for dental practices. Through this collaboration, CyberSimple® powered by CHECKLIGHT® will be made available via TeleDental.com and DentalChat.com, initially extending protection to more than 358 dental clinics nationwide, with significant expansion potential across the broader U.S. dental market. This effort underline

    1/15/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26

    CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at http

    2/5/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7647402. A live and recorded webcast of the event will be available on the Pulse Bioscie

    2/4/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Supermicro Announces Second Quarter Fiscal Year 2026 Financial Results

    Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company"), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced unaudited financial results for its second quarter of fiscal year 2026 ended December 31, 2025. Second Quarter Fiscal Year 2026 Highlights Net sales of $12.7 billion versus $5.0 billion in Q1'26 and $5.7 billion in Q2'25 Gross margin of 6.3% versus 9.3% in Q1'26 and 11.8% in Q2'25 Net income of $401 million versus $168 million in Q1'26 and $321 million in Q2'25 Diluted net income per common share of $0.60 versus $0.26 in Q1'26 and $0.51 in Q2'25 Non-GAAP gross margin of 6.4% versus 11.9% in Q2'25 Non-GAAP diluted net

    2/3/26 4:51:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ACC
    $AIM
    $ANNX
    $ARQQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care